Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-γ: A role for intrinsic tumor immunogenicity and IL-15

Cancer Research

Volumn 62, Issue 15, 2002, Pages 4390-4397

  Gri, Giorgia ^a   Chiodoni, Claudia ^a   Gallo, Elena ^a   Stoppacciaro, Antonella ^b   Liew, Foo Y ^c   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 15; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; ELECTROPHORESIS; FLOW CYTOMETRY; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; KNOCKOUT MOUSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ADENOCARCINOMA; ANIMALS; CELL DIVISION; COLONIC NEOPLASMS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0036682375     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
2. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
3. In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma
4. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-y production by anti-tumor T cells
5. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte endothelial cell cross-talk
6. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
7. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12
8. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: Implications for the antitumor activity of interleukin 12 and/or interleukin 2
9. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with INF-12
10. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
11. γ-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins
12. Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-γ with patterns of tissue expression that suggest nonredundant roles in vivo
13. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12
14. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo
15. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
16. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12
17. Cellular responses to interferon-γ
18. Interaction between the components of the interferon γ receptor complex
19. Other kinases can substitute for Jak2 in signal transduction by interferon-γ
20. Interferon γ-induced transcription of the high-affinity Fc receptor for IgG requires assembly of a complex that includes the 91-kDa subunit of transcription factor ISGF3
21. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
22. IL12 receptors and receptor antagonists
23. Interferon γ-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte/macrophage colony-stimulating factor
24. Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation
25. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
26. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
27. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors
28. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure
29. TS/A: A new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma
30. Multiple defects of immune cell function in mice with disrupted interferon-γ genes
31. Soluble IL-15 receptor a-chain administration prevents murine collagen- induced arthritis: A role for IL-15 in development of antigen-induced immunopathotogy
32. The Sushi domain of soluble IL-15 receptor a is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo
33. Improved retroviral vectors for gene transfer and expression
34. Construction and use of a safe and efficient amphotropic packaging cell line
35. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo
36. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12
37. Amount of interleukin 12 available at the tumor site is critical for tumor regression
38. Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells
39. GAS elements: A few nucleotides with a major impact on cytokine-induced gene expression
40. Stat1-independent regulation of gene expression in response to IFN-γ
41. Biologic consequences of Stat1-independent IFN signaling
42. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product
43. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors
44. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand
45. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice
46. Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model
47. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement
48. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation
49. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice
50. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells
51. Different requirements for α-galactosylceramide and, recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases
52. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
53. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
54. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN α receptor expression by nonhematopoietic cells
55. IFN can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen
56. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy
57. Interleukin 15: Biology and relevance to human disease